Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Abstract

Few studies evaluated the long-term safety of drugs for ADHD. Heterogeneity in follow-up duration and in data reporting made comparing different studies and drugs difficult. A systematic monitoring of long-term safety is needed.

Seeking Web-Based Information About Attention Deficit Hyperactivity Disorder: Where, What, and When

“…Nowadays, medication use is highly common worldwide and is still the mainstay of ADHD treatment in the United States [3]. Consequently, this finding supports this population’s need for more research and knowledge about addressing dilemmas bound with taking medication, which is a source of daily stress [41-43]. Furthermore, as previously revealed, 37 of 57 ADHD websites were in fact funded by drug companies.…”

An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder

“…A recent review of published prospective clinical trials shows that most adverse events are mild for methylphenidate and atomoxetine used for ADHD in children and adolescents (Clavenna and Bonati 2014). In our present study, both OROS-methylphenidate and atomoxetine were safe and well tolerated, with only modest differences in tolerability between the two drugs.…”

Diagnosis and management of developmental coordination disorder

“…31 As with other research on this topic, the authors reported that most of the adverse effects were mild or moderate. We found no comparable studies of adverse effects of medications among children with developmental coordination disorder and concurrent ADHD.…”